血管抑素基因联合氟尿嘧啶腹腔化疗预防大肠癌术后肝转移的实验
杜卫东,袁祖荣,沈达明, 黄春锦, 唐健雄,程爱群, 上海市华东医院普外科 上海市 200040
乔伟伟,复旦大学动物实验部 上海市 200032
张赣生,王一倩,于晓峰, 竺越,上海市华东医院消化科 上海市 200040
通讯作者:杜卫东,200040, 上海市华东医院普外科.
收稿日期:2005-03-12 接受日期:2005-04-20
摘要目的:观察血管抑素基因联合氟尿嘧啶腹腔化疗对预防大肠癌术后肝转移的作用.
, http://www.100md.com
方法:RT-PCR克隆血管抑素基因，建立重组腺病毒载体.建立人结肠癌LoVo肝转移种植的模型，给予血管抑素基因联合氟尿嘧啶腹腔化疗.观察其对大肠癌细胞肝转移的影响.
结果:血管抑素基因联合氟尿嘧啶腹腔化疗治疗组肝转移发生率明显低于其他各组(P<0.05)，肝转移瘤数少于其他各组(P<0.05)，荷瘤生存时间长，治疗组肿瘤组织中血管抑素基因表达为阳性，MVD明显低于其他各组.
结论:血管抑素的基因治疗与传统的腹腔化疗联合应用，对预防裸鼠人LoVo结肠癌细胞肝转移有一定的作用.
杜卫东,袁祖荣, 沈达明,乔伟伟,黄春锦, 唐健雄,程爱群,张赣生, 王一倩,于晓峰,竺越. 血管抑素基因联合氟尿嘧啶腹腔化疗预防大肠癌术后肝转移的实验.世界华人消化杂志 2005;13(12):1449-1451
, 百拇医药
Yu W, Whang I, Chung HY, Averbach A, SugarbakerPH. Indications for early postoperative intraperitoneal
chemotherapy of advanced gastric cancer:results of a prospective randomized trial. World J Surg 2001;25:985-990
2 杜卫东, 袁祖荣, 唐健雄,沈达明, 程爱群, 于晓峰,钱敏, 竺越.进展期胃肠道肿瘤术后联合化疗的临床疗效观察.
外科理论与实践 2003;8:383-386
3 Scoff GA. Angiostatin and angiostatin-related proteins. CancerMetastasis Rev 2000;19:97-107
, http://www.100md.com
4 Plank MJ, Sleeman BD. A reinforced random walk model of tumourangiogenesis and anti-angiogenic strategies.
Math Med Biol 2003;20:135-181
5 Kirsch M, Santarius T, Black PM, Schackert G. Therapeutic anti-angiogenesisfor malignant brain tumors.
Oncologie 2001;24:423-430
6 Tarui T, Miles LA, Takada Y. Specific interaction of angiostatinwith intergrin alpha(V)beta3 in endothelial cells.
, 百拇医药
J Biol Chem 2001;276:39562-39568
7 Distler O, Neidhart M, Gay RE, Gay S. The molecular control ofangiogenesis. Int Rev Immunol 2002;21:33-49
8 Tanaka T, Cao Y, Folkman J, Fine HA. Viral vector-targeted anti-angiogenicgene therapy utilizing an angiostatin
complemetary DNA. Cancer Res 1998;58:3362-3369
9 Griscelli F, Li H, Cheong C, Opolon P, Bennaceur-Griscelli A,Vassal G, Soria J, Soria C, Lu H, Perricaudet M, Yeh P.
, 百拇医药
Combined effects of radiotherapy andangiostatin gene therapy in glioma tumor model. Proc Natl Acad Sci USA
2000;97:6698-6703
10 Ragnhammar P, Hafstrom L, Nygren P, Glimelius B; SBU-group. SwedishCouncil of Technology Assessment in Health
Care. A systematic overview of chemotherapyeffects in colorectal cancer. Acta Oncol 2001;40:282-308
11 Pestieau SR, Schnake KJ, Stuart OA, Sugarbaker PH. Impact ofcarrier solutions on pharmacokinetics of
, http://www.100md.com
intraperitoneal chemotherapy. CancerChemother Pharmacol 2001;47:269-276
12 Valentini V, Mantini G, Turriziani A, Balducci M, Trodella L.Research trends in the treatment of colorectal cancer.
Rays 2000;25:393-395
13 Elias D, Antoun S, Goharin A, Otmany AE, Puizillout JM, Lasser P.Research on the best chemohyperthermia technique
of treatment of peritoneal carcinomatosisafter complete resection. Int J Surg Investig 2000;1:431-439
14 杜卫东, 唐建雄, 袁祖荣,曹英鸣, 沈达明, 程爱群,项平, 竺越.老年进展期胃肠道肿瘤术后腹腔化疗的临床疗效观察.
中国实用外科杂志 2003;23:725-728
编辑 张海宁, 百拇医药( 杜卫东, 袁祖荣, 沈达明, 乔伟伟, 黄春锦, 唐健雄, 程爱群, 张赣生, 王一倩, 于晓峰, 竺 越)
乔伟伟,复旦大学动物实验部 上海市 200032
张赣生,王一倩,于晓峰, 竺越,上海市华东医院消化科 上海市 200040
通讯作者:杜卫东,200040, 上海市华东医院普外科.
收稿日期:2005-03-12 接受日期:2005-04-20
摘要目的:观察血管抑素基因联合氟尿嘧啶腹腔化疗对预防大肠癌术后肝转移的作用.
, http://www.100md.com
方法:RT-PCR克隆血管抑素基因，建立重组腺病毒载体.建立人结肠癌LoVo肝转移种植的模型，给予血管抑素基因联合氟尿嘧啶腹腔化疗.观察其对大肠癌细胞肝转移的影响.
结果:血管抑素基因联合氟尿嘧啶腹腔化疗治疗组肝转移发生率明显低于其他各组(P<0.05)，肝转移瘤数少于其他各组(P<0.05)，荷瘤生存时间长，治疗组肿瘤组织中血管抑素基因表达为阳性，MVD明显低于其他各组.
结论:血管抑素的基因治疗与传统的腹腔化疗联合应用，对预防裸鼠人LoVo结肠癌细胞肝转移有一定的作用.
杜卫东,袁祖荣, 沈达明,乔伟伟,黄春锦, 唐健雄,程爱群,张赣生, 王一倩,于晓峰,竺越. 血管抑素基因联合氟尿嘧啶腹腔化疗预防大肠癌术后肝转移的实验.世界华人消化杂志 2005;13(12):1449-1451
, 百拇医药
Yu W, Whang I, Chung HY, Averbach A, SugarbakerPH. Indications for early postoperative intraperitoneal
chemotherapy of advanced gastric cancer:results of a prospective randomized trial. World J Surg 2001;25:985-990
2 杜卫东, 袁祖荣, 唐健雄,沈达明, 程爱群, 于晓峰,钱敏, 竺越.进展期胃肠道肿瘤术后联合化疗的临床疗效观察.
外科理论与实践 2003;8:383-386
3 Scoff GA. Angiostatin and angiostatin-related proteins. CancerMetastasis Rev 2000;19:97-107
, http://www.100md.com
4 Plank MJ, Sleeman BD. A reinforced random walk model of tumourangiogenesis and anti-angiogenic strategies.
Math Med Biol 2003;20:135-181
5 Kirsch M, Santarius T, Black PM, Schackert G. Therapeutic anti-angiogenesisfor malignant brain tumors.
Oncologie 2001;24:423-430
6 Tarui T, Miles LA, Takada Y. Specific interaction of angiostatinwith intergrin alpha(V)beta3 in endothelial cells.
, 百拇医药
J Biol Chem 2001;276:39562-39568
7 Distler O, Neidhart M, Gay RE, Gay S. The molecular control ofangiogenesis. Int Rev Immunol 2002;21:33-49
8 Tanaka T, Cao Y, Folkman J, Fine HA. Viral vector-targeted anti-angiogenicgene therapy utilizing an angiostatin
complemetary DNA. Cancer Res 1998;58:3362-3369
9 Griscelli F, Li H, Cheong C, Opolon P, Bennaceur-Griscelli A,Vassal G, Soria J, Soria C, Lu H, Perricaudet M, Yeh P.
, 百拇医药
Combined effects of radiotherapy andangiostatin gene therapy in glioma tumor model. Proc Natl Acad Sci USA
2000;97:6698-6703
10 Ragnhammar P, Hafstrom L, Nygren P, Glimelius B; SBU-group. SwedishCouncil of Technology Assessment in Health
Care. A systematic overview of chemotherapyeffects in colorectal cancer. Acta Oncol 2001;40:282-308
11 Pestieau SR, Schnake KJ, Stuart OA, Sugarbaker PH. Impact ofcarrier solutions on pharmacokinetics of
, http://www.100md.com
intraperitoneal chemotherapy. CancerChemother Pharmacol 2001;47:269-276
12 Valentini V, Mantini G, Turriziani A, Balducci M, Trodella L.Research trends in the treatment of colorectal cancer.
Rays 2000;25:393-395
13 Elias D, Antoun S, Goharin A, Otmany AE, Puizillout JM, Lasser P.Research on the best chemohyperthermia technique
of treatment of peritoneal carcinomatosisafter complete resection. Int J Surg Investig 2000;1:431-439
14 杜卫东, 唐建雄, 袁祖荣,曹英鸣, 沈达明, 程爱群,项平, 竺越.老年进展期胃肠道肿瘤术后腹腔化疗的临床疗效观察.
中国实用外科杂志 2003;23:725-728
编辑 张海宁, 百拇医药( 杜卫东, 袁祖荣, 沈达明, 乔伟伟, 黄春锦, 唐健雄, 程爱群, 张赣生, 王一倩, 于晓峰, 竺 越)
